Betamipron

Synonyms: 倍他米隆; N-Benzoyl-β-alanine
Betamipron (N-benzoyl-β-alanine) 是一种碳青霉烯类 β-内酰胺类抗生素 (antibiotic),对大多数革兰阳性与革兰阴性需氧和厌氧菌均有抗菌活性,可靶向抑制肾脏有机阴离子转运体,缓解 Cisplatin (MS-E94993) 造成的肾损伤,且不会干扰顺铂的生物活性;它常与 panipenem 联用,可减弱 panipenem 产生的肾脏影响,并小幅促进盲肠内 Clostridium difficile 增殖,因此可用于肾损伤、细菌感染相关研究。
产品编号: MS-I90671 纯度: 98.69% CAS No.: 3440-28-6 分子式: C10H11NO3 分子量: 193.20
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
50g
询价
询价

产品描述

Betamipron (N-benzoyl-β-alanine) 是一种碳青霉烯类 β-内酰胺类抗生素 (antibiotic),对大多数革兰阳性与革兰阴性需氧和厌氧菌均有抗菌活性,可靶向抑制肾脏有机阴离子转运体,缓解 Cisplatin (MS-E94993) 造成的肾损伤,且不会干扰顺铂的生物活性;它常与 panipenem 联用,可减弱 panipenem 产生的肾脏影响,并小幅促进盲肠内 Clostridium difficile 增殖,因此可用于肾损伤、细菌感染相关研究。

生物实验数据

生物活性 Betamipron (N-benzoyl-β-alanine) is a carbapenem β-lactam antibiotic (antibiotic) with antibacterial activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria; it targets and inhibits renal organic anion transporters, alleviates Cisplatin (MS-E94993)-induced kidney injury without interfering with the biological activity of cisplatin, and is commonly combined with panipenem to attenuate the renal effects of panipenem and slightly promote the proliferation of Clostridium difficile in the cecum, making it useful for research related to kidney injury and bacterial infection.
IC50 & Target

β-lactam

 

体外研究
(In Vitro)

Betamipron (与 panipenem 按 1:1 比例配伍) 可抑制肾脱氢肽酶-I 与肾脏阴离子转运功能,从而降低 panipenem 相关肾毒性,并阻止 panipenem 被肾脱氢肽酶-I 水解。

体内研究
(In Vivo)

Betamipron (100 mg/kg;皮下注射;每日 1 次;连续 5 天) 作为 1:1 配比的 panipenem/betamipron 制剂的组成成分,给药后第 7 天可导致小鼠盲肠内容物中艰难梭菌过度增殖。
Betamipron (250 mg/kg;腹腔注射;单次给药) 可显著抑制 Cisplatin (MS-E94993) 诱导的雄性 Wistar 大鼠肾毒性;可显著减轻雄性 ddY 小鼠由 Cisplatin 诱导的体重下降,并降低血清 BUN 水平;且不会改变顺铂对携带 P388 白血病的雄性 BDF1 小鼠的抗白血病疗效。

Animal Model: ICI strain (male, 5 weeks old, 20g)
Dosage: 100 mg/kg (as part of a 1:1 panipenem/betamipron formulation)
Administration: s.c.; once daily; 5 days
Result: Reduced Clostridium difficile counts in cecal contents to below 102 CFU/g in all 5 mice 1 day after the end of dosing.
Resulted in *Clostridium difficile* counts of 102 CFU/g in 1 mouse and 103 CFU/g in 4 mice 7 days after the end of dosing.
Animal Model: Wistar (male, 235-365 g, cisplatin-induced nephrotoxicity model)
ddY (male, 25-32 g, cisplatin-induced nephrotoxicity model)
BDF1 (male, 5 weeks old, 21-24.5 g, P388 leukemia model)
Dosage: 250 mg/kg
Administration: i.p.; single dose (1 hour after cisplatin)
Result: Blocked cisplatin-induced weight loss, with a 9.37% weight gain versus a 10.8% loss in the cisplatin group. Studies were conducted on male Wistar rats with cisplatin-induced nephrotoxicity.
Decreased serum BUN and creatinine to normal levels, which remained high in rats given cisplatin alone. Studies were conducted on male Wistar rats with cisplatin-induced nephrotoxicity.
Recovered cisplatin-altered water intake, urine volume and pH. Studies were conducted on male Wistar rats with cisplatin-induced nephrotoxicity.
Normalized abnormal urinary biochemical indicators caused by cisplatin. Studies were conducted on male Wistar rats with cisplatin-induced nephrotoxicity.
Mitigated cisplatin-triggered weight loss obviously compared with the combination of cisplatin and alkaline solution. Studies were conducted on male ddY mice with cisplatin-induced nephrotoxicity.
Reduced elevated serum BUN in mice receiving cisplatin plus alkaline solution. Studies were conducted on male ddY mice with cisplatin-induced nephrotoxicity.
Achieved similar survival benefits as cisplatin combined with alkaline solution. Studies were conducted on male BDF1 mice with P388 leukemia.
Extended survival in all cisplatin-treated mice compared with controls. Studies were conducted on male BDF1 mice with P388 leukemia.
性状 固体
颜色 White to off-white

化学信息

分子量 193.20
分子式 C10H11NO3
CAS No. 3440-28-6
别名 倍他米隆; N-Benzoyl-β-alanine

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.00 mg/mL (10.35 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (517.60 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM5.1760 mL25.8799 mL51.7598 mL129.3996 mL
5 mM1.0352 mL5.1760 mL10.3520 mL25.8799 mL
10 mM0.5176 mL2.5880 mL5.1760 mL12.9400 mL
15 mM0.3451 mL1.7253 mL3.4507 mL8.6266 mL
20 mM0.2588 mL1.2940 mL2.5880 mL6.4700 mL
25 mM0.2070 mL1.0352 mL2.0704 mL5.1760 mL
30 mM0.1725 mL0.8627 mL1.7253 mL4.3133 mL
40 mM0.1294 mL0.6470 mL1.2940 mL3.2350 mL
50 mM0.1035 mL0.5176 mL1.0352 mL2.5880 mL
60 mM0.0863 mL0.4313 mL0.8627 mL2.1567 mL
80 mM0.0647 mL0.3235 mL0.6470 mL1.6175 mL
100 mM0.0518 mL0.2588 mL0.5176 mL1.2940 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础